Nomura Asset Management Co. Ltd. Purchases 5,172 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Nomura Asset Management Co. Ltd. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 20.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,935 shares of the biotechnology company’s stock after acquiring an additional 5,172 shares during the period. Nomura Asset Management Co. Ltd. owned approximately 0.05% of Blueprint Medicines worth $3,206,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jackson Creek Investment Advisors LLC acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $1,102,000. CWM LLC acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $34,000. Peregrine Capital Management LLC raised its position in shares of Blueprint Medicines by 2.9% in the fourth quarter. Peregrine Capital Management LLC now owns 123,669 shares of the biotechnology company’s stock valued at $13,246,000 after buying an additional 3,500 shares in the last quarter. Illinois Municipal Retirement Fund acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $367,000. Finally, State of New Jersey Common Pension Fund D raised its position in shares of Blueprint Medicines by 0.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 35,131 shares of the biotechnology company’s stock valued at $3,763,000 after buying an additional 175 shares in the last quarter.

Shares of Blueprint Medicines stock opened at $69.59 on Monday. Blueprint Medicines Co. has a twelve month low of $53.26 and a twelve month high of $117.86. The business has a fifty day simple moving average of $67.22.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last issued its quarterly earnings data on Tuesday, February 15th. The biotechnology company reported ($5.40) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($4.73). Blueprint Medicines had a negative return on equity of 31.04% and a negative net margin of 357.66%. The business had revenue of $107.00 million during the quarter, compared to the consensus estimate of $104.14 million. During the same period in the prior year, the firm earned ($1.53) EPS. The business’s revenue for the quarter was up 213.8% compared to the same quarter last year. On average, analysts forecast that Blueprint Medicines Co. will post -7.44 EPS for the current year.

Several research analysts have commented on BPMC shares. Citigroup began coverage on shares of Blueprint Medicines in a research report on Monday, February 28th. They set a “neutral” rating and a $71.00 price objective for the company. Guggenheim upped their price target on shares of Blueprint Medicines from $120.00 to $122.00 in a report on Monday, January 3rd. SVB Leerink lowered their price target on shares of Blueprint Medicines from $93.00 to $82.00 and set a “market perform” rating for the company in a report on Thursday, February 17th. StockNews.com began coverage on shares of Blueprint Medicines in a report on Thursday, March 31st. They set a “sell” rating for the company. Finally, Wedbush reiterated an “outperform” rating and set a $126.00 price target on shares of Blueprint Medicines in a report on Monday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $106.64.

In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Wednesday, April 6th. The shares were sold at an average price of $70.11, for a total transaction of $350,550.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ariel Hurley sold 761 shares of the company’s stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $60.27, for a total transaction of $45,865.47. The disclosure for this sale can be found here. Insiders have sold 10,575 shares of company stock worth $677,614 in the last ninety days. Insiders own 3.34% of the company’s stock.

About Blueprint Medicines (Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Featured Articles

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.